Effects of interferon alpha on myeloma cells: mechanisms of differential responsiveness.
Jelinek
D F
DF
Department of Immunology, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA.
Arora
T
T
D002455:Cell Division / Q000187:drug effects; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004268:DNA-Binding Proteins / Q000378:metabolism; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology*; D015850:Interleukin-6 / Q000494:pharmacology; D008954:Models, Biological; D009101:Multiple Myeloma / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins; D015398:Signal Transduction; D015534:Trans-Activators / Q000378:metabolism; D014407:Tumor Cells, Cultured
D004273:DNA, Neoplasm; D004268:DNA-Binding Proteins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D015850:Interleukin-6; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011994:Recombinant Proteins; D015534:Trans-Activators